The 2022 guidelines issued by the American Diabetes Association (ADA) and the Kidney Disease Improving Global Outcomes (KDIGO) recommend the use of finerenone across a wide range of DKD patients with increased albuminuria despite treatment with an ACEI/ARB and SGLT2 inhibitor [124,160]. Here, SLC5A2 is linked to diabetic kidney disease.